Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Neuradiab + bevacizumab
- Development stage
- Unknown
- Lead developer
- Bradmer Pharmaceuticals
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intracavitary, Intravenous
01
Overview
Neuradiab + bevacizumab is a combination therapy under investigation for the treatment of glioblastoma multiforme (GBM), an aggressive form of brain cancer. Neuradiab is a radiolabeled monoclonal antibody (anti-tenascin) conjugated to radioactive iodine-131 that delivers targeted radiation to residual tumor cells after surgery with minimal impact on normal brain tissue. Bevacizumab is a recombinant humanized monoclonal antibody that inhibits angiogenesis by binding and neutralizing vascular endothelial growth factor A (VEGF-A), thereby reducing blood vessel formation in tumors and inhibiting their growth. The combination aims to enhance tumor cell killing through both direct radiotherapy and inhibition of tumor vascularization[2][7].
- Brand names
- AvastinAlymsysJobevneMvasiVegzelmaZirabev
- Other names
- neuradiab131I anti-tenascin monoclonal antibody 81c6
02
Targets
VEGFA (Vascular endothelial growth factor A)TNC (Tenascin-C fibronectin type III domains)
Beyond the preview
Go deeper on Neuradiab + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neuradiab + bevacizumab.